HK1126223A1 - Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration - Google Patents
Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degenerationInfo
- Publication number
- HK1126223A1 HK1126223A1 HK09104433.8A HK09104433A HK1126223A1 HK 1126223 A1 HK1126223 A1 HK 1126223A1 HK 09104433 A HK09104433 A HK 09104433A HK 1126223 A1 HK1126223 A1 HK 1126223A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- age
- cfhr
- macular degeneration
- related macular
- Prior art date
Links
- 206010064930 age-related macular degeneration Diseases 0.000 title abstract 4
- 208000002780 macular degeneration Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 208000019553 vascular disease Diseases 0.000 title abstract 3
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010002329 Aneurysm Diseases 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 210000003917 human chromosome Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83101806P | 2006-07-13 | 2006-07-13 | |
US84007306P | 2006-08-23 | 2006-08-23 | |
PCT/US2007/073514 WO2008008986A2 (fr) | 2006-07-13 | 2007-07-13 | Procédés et réactifs pour le traitement et le diagnostic de troubles vasculaires et de la dégénérescence maculaire liée à l'age |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1126223A1 true HK1126223A1 (en) | 2009-08-28 |
Family
ID=38924245
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09104433.8A HK1126223A1 (en) | 2006-07-13 | 2009-05-14 | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
HK12109179.0A HK1168360A1 (en) | 2006-07-13 | 2012-09-18 | Methods and reagents for treatment of age-related macular degeneration |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12109179.0A HK1168360A1 (en) | 2006-07-13 | 2012-09-18 | Methods and reagents for treatment of age-related macular degeneration |
Country Status (12)
Country | Link |
---|---|
US (4) | US7867727B2 (fr) |
EP (3) | EP2479284B1 (fr) |
JP (1) | JP5431151B2 (fr) |
AT (1) | ATE551350T1 (fr) |
AU (1) | AU2007272335B2 (fr) |
CA (1) | CA2659392A1 (fr) |
DK (1) | DK2447275T3 (fr) |
HK (2) | HK1126223A1 (fr) |
IL (1) | IL196319A0 (fr) |
NZ (1) | NZ574046A (fr) |
SG (1) | SG173371A1 (fr) |
WO (1) | WO2008008986A2 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2302076B1 (fr) * | 2005-02-14 | 2014-11-12 | University of Iowa Research Foundation | Procédés et réactifs pour le traitement et le diagnostic de la dégénération maculaire liée à l'âge |
US20080146501A1 (en) * | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
JP2009544317A (ja) * | 2006-07-26 | 2009-12-17 | イェール ユニバーシティー | 加齢性黄斑変性の診断および治療 |
WO2009059321A2 (fr) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Analyse de lieu de rca pour estimer la sensibilité à l'amd et au mpgnii |
JP2011510297A (ja) * | 2008-01-18 | 2011-03-31 | バトリックス・メディカル・インコーポレイテッド | 動脈瘤のための診断バイオマーカー |
DE102008049136B4 (de) * | 2008-09-26 | 2012-10-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. | Neue Regulatoren des angeborenen Immunsystems |
CA2768237A1 (fr) * | 2009-07-16 | 2011-01-20 | Glaxo Wellcome Manufacturing Pte Ltd | Methode de traitement |
WO2011017229A2 (fr) * | 2009-08-06 | 2011-02-10 | Tufts - New England Medical Center | Composants de complément plasmatique en tant que marqueurs d'expression pour la dégénérescence maculaire liée à l'âge et les phénotypes afférents |
US20120241321A1 (en) * | 2009-09-14 | 2012-09-27 | Harald Mischak | Polypeptide marker for diagnosing and assessing vascular diseases |
JP5706612B2 (ja) * | 2009-12-28 | 2015-04-22 | 学校法人 埼玉医科大学 | 加齢黄斑変性症易罹患性の判定マーカー並びに判定方法及び判定キット |
WO2012051462A2 (fr) * | 2010-10-14 | 2012-04-19 | Sequenom, Inc. | Variations du nombre de copies du facteur h du complément dans le locus rca |
WO2012112955A2 (fr) | 2011-02-17 | 2012-08-23 | The Trustees Of Columbia University In The City Of New York | Procédés d'identification de sujets présentant un risque génétique de développer une néphropathie à iga |
SG194235A1 (en) * | 2011-04-29 | 2013-12-30 | Univ Utah Res Found | Methods of predicting the development of complement-mediated disease |
JP2013064616A (ja) * | 2011-09-15 | 2013-04-11 | Osaka Univ | 高度動脈硬化を発症している可能性を検出する方法およびその利用 |
WO2013150132A2 (fr) * | 2012-04-05 | 2013-10-10 | Mosaiques Diagnostics And Therapeutics Ag | Marqueurs polypeptidiques pour diagnostiquer et évaluer des accidents vasculaires cérébraux |
GB201301632D0 (en) * | 2013-01-30 | 2013-03-13 | Imp Innovations | Complement System |
WO2014131714A1 (fr) * | 2013-02-26 | 2014-09-04 | Roche Diagnostics Gmbh | Agents, kits et méthodes pour la détection de la protéine 1 associée au facteur h du complément |
WO2014169294A1 (fr) | 2013-04-12 | 2014-10-16 | The Trustees Of Columbia University In The City Of New York | Mutations dans dstyk provoquant des malformations dominantes dans les voies urinaires |
WO2014194213A1 (fr) * | 2013-05-30 | 2014-12-04 | University Of Iowa Research Foundation | Protéines de complément spécifiques et efficacité d'une thérapie par les anticorps |
US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
CA3009553A1 (fr) | 2015-12-23 | 2017-06-29 | Centre National De La Recherche Scientifique | Agents inhibant la liaison de cfh a cd11b/cd18 et leurs utilisations |
US11142548B2 (en) | 2016-05-10 | 2021-10-12 | Sorbonne Universite | Agents that activate CD47 and their use in the treatment of inflammation |
WO2019215330A1 (fr) * | 2018-05-10 | 2019-11-14 | The University Of Manchester | Méthodes d'évaluation de la dégénérescence maculaire |
DE102018120016B4 (de) * | 2018-08-16 | 2020-09-03 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- | Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung |
US20220146530A1 (en) * | 2019-03-07 | 2022-05-12 | Reti Mark Co., Ltd. | A combination of biomarkers for diagnosing of age-related macular degeneration and use thereof |
JP2022526429A (ja) | 2019-04-10 | 2022-05-24 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | Amdの処置のためのhtra1調節 |
US20210123076A1 (en) * | 2019-10-22 | 2021-04-29 | Applied Genetic Technologies Corporation | Adeno-associated virus (aav)vectors for the treatment of age-related macular degeneration and other ocular diseases and disorders |
WO2022058447A1 (fr) * | 2020-09-16 | 2022-03-24 | The University Of Manchester | Test du « complémentome » |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US5037746A (en) | 1986-12-03 | 1991-08-06 | University Patents, Inc. | RNA ribozyme polymerases, and methods |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
AU632494B2 (en) | 1988-05-20 | 1993-01-07 | F. Hoffmann-La Roche Ag | Immobilized sequence-specific probes |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5180818A (en) | 1990-03-21 | 1993-01-19 | The University Of Colorado Foundation, Inc. | Site specific cleavage of single-stranded dna |
US20020032313A1 (en) * | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
EP1413587A2 (fr) | 1991-05-03 | 2004-04-28 | Washington University | Régulateur modifié du système de complément |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
EP0655090B1 (fr) | 1992-04-27 | 2000-12-27 | The Trustees Of Dartmouth College | Detection de sequences geniques dans des liquides biologiques |
AU5961994A (en) | 1993-01-22 | 1994-08-15 | University Research Corporation | Localization of therapeutic agents |
US5667969A (en) | 1993-11-12 | 1997-09-16 | University Research Corporation | Alteration of sequence of a deleterious target molecule by ribozyme catalyzed trans-splicing |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US6706471B1 (en) | 1996-01-24 | 2004-03-16 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
GB9710475D0 (en) | 1997-05-21 | 1997-07-16 | Zeneca Ltd | Gene silencing |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
NZ507093A (en) | 1998-04-08 | 2003-08-29 | Commw Scient Ind Res Org | Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant |
AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
US20020102581A1 (en) | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
ATE343792T1 (de) | 1999-02-19 | 2006-11-15 | Univ Iowa Res Found | Diagnostika und therapeutika für maculare degeneration |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
CA2404890C (fr) | 2000-03-30 | 2013-11-19 | Whitehead Institute For Biomedical Research | Mediateurs d'interference arn specifiques de sequences arn |
DK2026073T3 (en) | 2000-04-29 | 2016-07-25 | Univ Iowa Res Found | Diagnosis and treatment of macular degeneration-related disorders |
US6632606B1 (en) | 2000-06-12 | 2003-10-14 | Aclara Biosciences, Inc. | Methods for single nucleotide polymorphism detection |
ES2215494T5 (es) | 2000-12-01 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Moléculas de RNA pequeñas que median la interferencia de RNA |
AUPR604101A0 (en) | 2001-06-29 | 2001-07-26 | Unisearch Limited | Aptamers |
US7255858B2 (en) | 2001-08-10 | 2007-08-14 | University Of Virginia Patent Foundation | Enhancing the efficacy of immunotherapies by supplementing with complement |
EP1836312B1 (fr) * | 2004-11-18 | 2011-10-12 | Yale University | Methodes et preparations pour le diagnostic de la la dégénération maculaire liée à l'âge |
EP2302076B1 (fr) | 2005-02-14 | 2014-11-12 | University of Iowa Research Foundation | Procédés et réactifs pour le traitement et le diagnostic de la dégénération maculaire liée à l'âge |
US7695909B2 (en) | 2005-06-08 | 2010-04-13 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26 |
WO2007044897A1 (fr) | 2005-10-11 | 2007-04-19 | Yale University | Genes associes a la degenerescence maculaire |
EP1941061A1 (fr) | 2005-11-02 | 2008-07-09 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Procédé élaboré pour la reconnaissance et le test de la dégénérescence maculaire liée à l'âge (dmla) |
US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
US20080146501A1 (en) | 2006-02-13 | 2008-06-19 | University Of Iowa Research Foundation | Protective complement proteins and age-related macular degeneration |
GB0611606D0 (en) * | 2006-06-13 | 2006-07-19 | Univ Belfast | Protection against and treatment of age related macular degeneration |
-
2007
- 2007-07-13 EP EP12152172.8A patent/EP2479284B1/fr not_active Not-in-force
- 2007-07-13 SG SG2011050705A patent/SG173371A1/en unknown
- 2007-07-13 AT AT07812932T patent/ATE551350T1/de active
- 2007-07-13 JP JP2009519713A patent/JP5431151B2/ja active Active
- 2007-07-13 DK DK12152177.7T patent/DK2447275T3/en active
- 2007-07-13 AU AU2007272335A patent/AU2007272335B2/en not_active Ceased
- 2007-07-13 CA CA002659392A patent/CA2659392A1/fr not_active Abandoned
- 2007-07-13 EP EP12152177.7A patent/EP2447275B1/fr active Active
- 2007-07-13 WO PCT/US2007/073514 patent/WO2008008986A2/fr active Application Filing
- 2007-07-13 EP EP07812932A patent/EP2046807B1/fr active Active
- 2007-07-13 NZ NZ574046A patent/NZ574046A/xx not_active IP Right Cessation
- 2007-08-20 US US11/894,667 patent/US7867727B2/en not_active Expired - Fee Related
-
2009
- 2009-01-01 IL IL196319A patent/IL196319A0/en unknown
- 2009-05-14 HK HK09104433.8A patent/HK1126223A1/xx not_active IP Right Cessation
-
2010
- 2010-11-24 US US12/954,425 patent/US20120040884A1/en not_active Abandoned
-
2012
- 2012-09-18 HK HK12109179.0A patent/HK1168360A1/xx not_active IP Right Cessation
-
2014
- 2014-05-15 US US14/279,235 patent/US20150050646A1/en not_active Abandoned
-
2018
- 2018-03-05 US US15/912,379 patent/US20180371547A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20080152659A1 (en) | 2008-06-26 |
IL196319A0 (en) | 2009-09-22 |
DK2447275T3 (en) | 2015-06-29 |
US20180371547A1 (en) | 2018-12-27 |
US20150050646A1 (en) | 2015-02-19 |
EP2479284B1 (fr) | 2017-09-20 |
US7867727B2 (en) | 2011-01-11 |
AU2007272335A1 (en) | 2008-01-17 |
WO2008008986A2 (fr) | 2008-01-17 |
ATE551350T1 (de) | 2012-04-15 |
HK1168360A1 (en) | 2012-12-28 |
EP2046807A4 (fr) | 2009-10-28 |
EP2479284A2 (fr) | 2012-07-25 |
EP2046807A2 (fr) | 2009-04-15 |
EP2479284A3 (fr) | 2012-08-08 |
EP2046807B1 (fr) | 2012-03-28 |
EP2447275A1 (fr) | 2012-05-02 |
SG173371A1 (en) | 2011-08-29 |
AU2007272335B2 (en) | 2014-03-27 |
JP5431151B2 (ja) | 2014-03-05 |
NZ574046A (en) | 2012-09-28 |
WO2008008986A3 (fr) | 2008-10-23 |
EP2447275B1 (fr) | 2015-04-01 |
US20120040884A1 (en) | 2012-02-16 |
JP2009544280A (ja) | 2009-12-17 |
CA2659392A1 (fr) | 2008-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1126223A1 (en) | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration | |
WO2009059318A3 (fr) | Gènes et polymorphismes associés à l'amd | |
Gregson et al. | A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date | |
WO2006062716A3 (fr) | Methodes et preparations pour le traitement de troubles oculaires | |
MX2009009738A (es) | Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento. | |
WO2006002262A3 (fr) | Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs | |
WO2008008433A3 (fr) | Acylanilides substitués et procédés d'utilisation de ceux-ci | |
WO2008052798A3 (fr) | Fgfr4 favorise la résistance des cellules cancéreuses en réponse aux médicaments chimiothérapiques | |
WO2005020972A3 (fr) | Polytherapie pour le traitement de troubles neovasculaires oculaires | |
NZ595305A (en) | Methods and reagents for treatment and diagnosis of age-related macular degeneration | |
WO2007022506A3 (fr) | Méthodes et préparations pour le traitement d'une maladie neurologique | |
NO20084488L (no) | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | |
WO2008137762A3 (fr) | Procédés de diagnostic et de traitement de la maladie de crohn | |
WO2003013535A3 (fr) | Moyens et methodes de traitement ameliore du cancer fondes sur mdr1 | |
MX2012013613A (es) | Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. | |
WO2008074329A3 (fr) | Modulation de l'activité de pro-neurotrophines | |
WO2004009610A3 (fr) | Utilisation de composes nucleosidiques pour la suppression non-sens et le traitement de maladies genetiques | |
WO2008143774A3 (fr) | Procédés et compositions permettant de déterminer l'hétérozygocité snp dans le cadre d'un diagnostic et d'une thérapie allèle-spécifiques | |
WO2006029142A3 (fr) | Methodes et systemes de traitement de l'asthme et d'autres maladies respiratoires | |
WO2005110056A3 (fr) | Compositions contenant des recepteurs d'addl, compositions et methodes associees | |
NO20055884L (no) | Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt | |
WO2006078853A3 (fr) | Proteine d'interaction avec la thioredoxine (txnip) en tant que regulateur de la fonction vasculaire | |
WO2006131512A3 (fr) | Agents antithrombiques | |
WO2004006856A3 (fr) | Sequestration ou elimination du fer pour reduire la neurodegenerescence ou la progression de la maladie de parkinson | |
WO2006076695A3 (fr) | Criblage genetique destine a ameliorer le traitement de patients diagnostiques comme depressifs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230713 |